WO2023078252A1 - Pparg inverse agonists and uses thereof - Google Patents

Pparg inverse agonists and uses thereof Download PDF

Info

Publication number
WO2023078252A1
WO2023078252A1 PCT/CN2022/129034 CN2022129034W WO2023078252A1 WO 2023078252 A1 WO2023078252 A1 WO 2023078252A1 CN 2022129034 W CN2022129034 W CN 2022129034W WO 2023078252 A1 WO2023078252 A1 WO 2023078252A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/129034
Other languages
English (en)
French (fr)
Inventor
Danmei Dai
Bo Zheng
Fei Wang
Liqing CONG
Yaohui Huang
Runyan LI
Xiaoyang Wang
Peter Wade
Jonathan E. Wilson
James E. Audia
Jacob I. STUCKEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flare Therapeutics Inc
Original Assignee
Flare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL312547A priority Critical patent/IL312547A/en
Priority to RS20251169A priority patent/RS67425B1/sr
Priority to AU2022380979A priority patent/AU2022380979A1/en
Priority to FIEP22809321.7T priority patent/FI4426434T3/fi
Priority to MDE20240849T priority patent/MD4426434T2/ro
Priority to CA3237199A priority patent/CA3237199A1/en
Priority to KR1020247017817A priority patent/KR20240144096A/ko
Priority to CN202280086503.8A priority patent/CN119677720A/zh
Priority to ES22809321T priority patent/ES3053082T3/es
Priority to PL22809321.7T priority patent/PL4426434T3/pl
Priority to LTEPPCT/CN2022/129034T priority patent/LT4426434T/lt
Priority to DK22809321.7T priority patent/DK4426434T3/da
Priority to EP25188854.1A priority patent/EP4653053A1/en
Priority to MA67105A priority patent/MA67105B1/fr
Priority to EP22809321.7A priority patent/EP4426434B1/en
Priority to HRP20251438TT priority patent/HRP20251438T1/hr
Priority to PE2024000994A priority patent/PE20250739A1/es
Priority to SI202230204T priority patent/SI4426434T1/sl
Priority to SM20250447T priority patent/SMT202500447T1/it
Application filed by Flare Therapeutics Inc filed Critical Flare Therapeutics Inc
Priority to JP2024526592A priority patent/JP2025508272A/ja
Priority to US18/130,121 priority patent/US11820747B2/en
Publication of WO2023078252A1 publication Critical patent/WO2023078252A1/en
Priority to MX2024005405A priority patent/MX2024005405A/es
Anticipated expiration legal-status Critical
Priority to US18/664,492 priority patent/US20250084038A1/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • PPARgamma is a type II ligand-dependent nuclear hormone receptor (belonging to the PPAR nuclear receptor subfamily) that functions as an obligate heterodimer with retinoid X receptors (RXRs) .
  • RXRs retinoid X receptors
  • PPARG is predominantly expressed in adipose tissue, colon, macrophages and the luminal layers of the urothelium.
  • PPARG is known as a master regulator of adipogenesis, functioning to regulate adipocyte differentiation, fatty acid storage and glucose metabolism.
  • PPARG has also been shown to play an important role in the metabolism and inflammation of macrophages, where it is induced by IL4 and controls glutamine metabolism. In the normal urothelium, PPARG is critical for its homeostasis and regeneration.
  • PPARG The role for PPARG in cancer was originally inferred from genomic studies that identified a PAX8-PPARG chromosomal rearrangement in follicular thyroid carcinomas. More recently, PPARG has been found to be over-expressed and genetically altered in the luminal subtype of urothelial cancer. This is consistent with reports that long-term use of PPARG agonists is associated with an increased incidence of urothelial cancer. Most urothelial cancers are urothelial carcinoma, which are classified as either non-muscle-invasive urothelial cancer (NMIUC, 70%) , muscle-invasive urothelial cancer (MIUC, 25%) or metastatic urothelial cancer (MUC, 5%) .
  • NMIUC non-muscle-invasive urothelial cancer
  • MIUC muscle-invasive urothelial cancer
  • MUC metastatic urothelial cancer
  • MIUC is usually diagnosed de novo but may arise from the 10 to 20%of NMIUC cases that eventually progress. MIUC is a heterogeneous and aggressive disease, associated with a five-year survival rate of 60%for patients with localized disease and less than 10%for patients with distant metastases. Molecular understanding of NMIUC and MIUC has improved significantly, including the association between molecular subtypes and urothelial differentiation. Several molecular classes of MIUC have been proposed, whereby an activated PPARG signature features prominently in the luminal subtypes. First-line treatment is chemotherapy with several options in chemo-ineligible or second line, but treatment options are limited with poor overall survival rates.
  • PPARG modulators for treating cancers such as NMIUC, MIUC, and MUC, and related conditions.
  • the disclosed compounds of Formula I and pharmaceutically acceptable salts thereof modulate PPARG (e.g., as agonists such as inverse agonists, and are useful in a variety of therapeutic applications such as, for example, in treating cancer. As such, their uses for treating diseases responsive to the inhibition of PPARG are included.
  • PPARG e.g., as agonists such as inverse agonists
  • compositions comprising the compounds and pharmaceutically acceptable salts of the disclosed compounds of Formula I, as well as methods for their preparation are also included.
  • FIG. 1 depicts an X-ray powder diffraction pattern (XRPD) for crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile.
  • XRPD X-ray powder diffraction pattern
  • FIG. 2 depicts a differential scanning calorimetry (DSC) thermogram for Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile.
  • DSC differential scanning calorimetry
  • R 1 is hydrogen, halo, (C 1 -C 4 ) alkyl, or hydroxyl;
  • X is S, SO, SO 2 , or -SONH
  • R 2 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, or halo (C 1 -C 4 ) alkyl;
  • R 3 is cyano or nitro
  • R 4 is hydrogen, halo, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, or hydroxyl;
  • R 5 is halo, halo (C 1 -C 4 ) alkyl, or cyano
  • R 6 is halo, halo (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkyl, or cyano;
  • R 7 is halo, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, halo (C 1 -C 4 ) alkyl, halo (C 1 -C 4 ) alkoxy, - (C 1 -C 4 ) alkylOR a , - (C 1 -C 4 ) alkylC (O) R a , - (C 1 -C 4 ) alkylC (O) OR a , -C (O) NR a R b , - (C 1 -C 4 ) alkylC (O) NR a R b , -C (O) R a , -C (O) OR a , -NR a R b , - (C 1 -C 4 ) alkylNR a R b , -C (O) OR a , -NR a R b , - (C 1 -
  • R 8 is selected from halo, (C 1 -C 4 ) alkyl, halo (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, halo (C 1 -C 4 ) alkoxy, nitro, oxo, cyano, - (C 1 -C 4 ) alkylOR d , - (C 1 -C 4 ) alkylC (O) R d , - (C 1 -C 4 ) alkylC (O) OR d , -C (O) NR d R e , - (C 1 -C 4 ) alkylC (O) NR d R e , -C (O) R d , -C (O) OR d , -NR d R e , - (C 1 -C 4 ) alkylNR d R e , -C (O) R d , -C
  • R a , R b , R c , R d , R e , and R f are each independently hydrogen or (C 1 -C 4 ) alkyl;
  • q and r are each independently 0 or 1.
  • a hyphen designates the point of attachment of that group to the variable to which it is defined.
  • -NR b C (O) OR c and -NR b C (S) OR c mean that the point of attachment for this group occurs on the nitrogen atom.
  • halo and “halogen” refer to an atom selected from fluorine (fluoro, -F) , chlorine (chloro, -Cl) , bromine (bromo, -Br) , and iodine (iodo, -I) .
  • alkyl when used alone or as part of a larger moiety, such as “haloalkyl” , and the like, means saturated straight-chain or branched monovalent hydrocarbon radical.
  • Alkoxy means an alkyl radical attached through an oxygen linking atom, represented by –O-alkyl.
  • (C 1 -C 4 ) alkoxy includes methoxy, ethoxy, proproxy, and butoxy.
  • haloalkyl includes mono, poly, and perhaloalkyl groups where the halogens are independently selected from fluorine, chlorine, bromine, and iodine.
  • Haloalkoxy is a haloalkyl group which is attached to another moiety via an oxygen atom such as, e.g., –OCHF 2 or –OCF 3 .
  • 5-to 7-membered heteroaryl used alone or as part of a larger moiety refers to a 5-to 7-membered aromatic radical containing 1-4 heteroatoms selected from N, O, and S.
  • Monocyclic heteroaryl includes, for example, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, triazinyl, tetrazinyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, etc.
  • Optional substituents on a heteroaryl group may be present on any substitutable position and, include, e.g., the position at which the heteroaryl is attached.
  • 4-to 6-membered heterocyclyl means a 4-to 6-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S.
  • a heterocyclyl ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • Examples of monocyclic saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, oxazolidinyl, piperazinyl, dioxanyl, oxetanyl, dioxolanyl, morpholinyl, dihydrofuranyl, dihydropyranyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, and tetrahydropyrimidinyl.
  • Optional substituents on a heterocyclyl group may be present on any substitutable position and, include, e.g., the position at which the heterocyclyl is attached.
  • the disclosed compounds may exist in one or more tautomeric forms, such as those below, and are included herein.
  • crystalline refers to a solid form of a compound wherein there exists long-range atomic order in the positions of the atoms. The crystalline nature of a solid can be confirmed, for example, by examination of the X-ray powder diffraction pattern.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is a single crystalline form, meaning that 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is present as a single crystal or a plurality of crystals in which each crystal has the same crystal form (i.e., Form A) .
  • the 2-theta values of the X-ray powder diffraction patterns for the crystalline form described herein may vary slightly from one instrument to another and also depending on variations in sample preparation and batch to batch variation due to factors such as temperature variation, sample displacement, and the presence or absence of an internal standard. Therefore, unless otherwise defined, the XRPD patterns /assignments recited herein are not to be construed as absolute and can vary ⁇ 0.2 degrees. It is well known in the art that this variability will account for the above factors without hindering the unequivocal identification of a crystal form. Unless otherwise specified, the 2-theta values provided herein were obtained using Cu K ⁇ 1 radiation.
  • Temperature values, e.g., for DSC peaks herein may vary slightly from one instrument to another and also depending on variations in sample preparation, batch to batch variation, and environmental factors. Therefore, unless otherwise defined, temperature values recited herein are not to be construed as absolute and can vary ⁇ 5 degrees or ⁇ 2 degrees.
  • Substantially the same XRPD pattern” or “an X-ray powder diffraction pattern substantially similar to” a defined figure means that for comparison purposes, at least 90%of the peaks shown are present. It is to be further understood that for comparison purposes some variability in peak intensities from those shown are allowed, such as ⁇ 0.2 degrees.
  • subject and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like) , farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like) .
  • companion animals e.g., dogs, cats, and the like
  • farm animals e.g., cows, pigs, horses, sheep, goats and the like
  • laboratory animals e.g., rats, mice, guinea pigs and the like
  • the subject is a human in need of treatment.
  • inhibitor includes a decrease in the baseline activity of a biological activity or process.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
  • treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of exposure to a particular organism, or other susceptibility factors) , i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to delay their recurrence.
  • pharmaceutically acceptable carrier refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol
  • the salts of the compounds described herein refer to non-toxic “pharmaceutically acceptable salts. ”
  • Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include e.g., salts of inorganic acids (such as hydrochloric acid, hydrobromic, phosphoric, nitric, and sulfuric acids) and of organic acids (such as, acetic acid, benzenesulfonic, benzoic, methanesulfonic, and p-toluenesulfonic acids) .
  • Suitable pharmaceutically acceptable basic salts include e.g., ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts) .
  • Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like.
  • Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, benzoates and salts with amino acids such as glutamic acid.
  • an effective amount or “therapeutically effective amount” refers to an amount of a compound described herein that will elicit a desired or beneficial biological or medical response of a subject e.g., a dosage of between 0.01 -100 mg/kg body weight/day.
  • the compound of Formula I is of the Formula II:
  • the compound of Formula I is of the Formula II a :
  • the compound of Formula I is of the Formula III:
  • the compound of Formula I is of the Formula III a :
  • the compound of Formula I is of the Formula IV:
  • the compound of Formula I is of the Formula IV a :
  • R 1 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is hydrogen, wherein the remaining variables are as described above for Formula I.
  • R 3 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is cyano, wherein the remaining variables are as described above for Formula I or the third embodiment.
  • R 4 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is hydrogen, wherein the remaining variables are as described above for Formula I or any one of the third or fourth embodiments.
  • R 5 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is halo or cyano, wherein the remaining variables are as described above for Formula I or any one of the third, fourth, or fifth embodiments.
  • R 5 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is halo, wherein the remaining variables are as described above for Formula I or any one of the third, fourth, or fifth embodiments.
  • R 5 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is chloro or fluoro, wherein the remaining variables are as described above for Formula I or any one of the third, fourth, or fifth embodiments.
  • R 5 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is fluoro, wherein the remaining variables are as described above for Formula I or any one of the third, fourth, or fifth embodiments.
  • R 6 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is halo, wherein the remaining variables are as described above for Formula I or any one of the third to sixth embodiments.
  • R 6 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is fluoro or chloro, wherein the remaining variables are as described above for Formula I or any one of the third to sixth embodiments.
  • R 6 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is fluoro, wherein the remaining variables are as described above for Formula I or any one of the third to sixth embodiments.
  • R 7 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is halo, halo (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, - (C 1 -C 4 ) alkylOR a , -C (O) NR a R b , phenyl, 4-to 6-membered heterocyclyl, and 5-to 7-membered heteroaryl, wherein each of said phenyl, 4-to 6-membered heterocyclyl, and 5-to 7-membered heteroaryl are optionally and independently substituted with 1 to 3 groups selected from R 8 , wherein the remaining variables are as described above for Formula I or any one of the third to seventh embodiments.
  • R 7 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is halo, halo (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, - (C 1 -C 4 ) alkylOR a , -C (O) NR a R b , phenyl, pyridinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl, pyrazolyl, and oxetanyl, wherein each of said phenyl, pyridinyl, pyrazolyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, piperidinyl, and oxetanyl are optionally and independently substituted with 1 to 3 groups selected from R 8 , wherein the remaining variables are as described above for Formula I or
  • R 7 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is halo, halo (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, - (C 1 -C 4 ) alkylOR a , -C (O) NR a R b , phenyl, pyridinyl, pyrazolyl, and oxetanyl, wherein each of said phenyl, pyridinyl, pyrazolyl, and oxetanyl are optionally and independently substituted with 1 to 3 groups selected from R 8 , wherein the remaining variables are as described above for Formula I or any one of the third to seventh embodiments.
  • R 7 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is pyrazolyl, pyridinyl, or piperazinyl, each of which optionally and independently substituted with 1 to 3 groups selected from R 8 , wherein the remaining variables are as described above for Formula I or any one of the third to seventh embodiments.
  • R 7 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is pyrazolyl optionally and independently substituted with 1 to 3 groups selected from R 8 , wherein the remaining variables are as described above for Formula I or any one of the third to seventh embodiments.
  • R 8 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is selected from halo, (C 1 -C 4 ) alkyl, halo (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, halo (C 1 -C 4 ) alkoxy, oxo, and cyano, wherein the remaining variables are as described above for Formula I or any one of the third to eighth embodiments.
  • R 8 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is halo (C 1 -C 4 ) alkyl, wherein the remaining variables are as described above for Formula I or any one of the third to eighth embodiments.
  • R 8 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is (C 1 -C 4 ) alkyl, wherein the remaining variables are as described above for Formula I or any one of the third to eighth embodiments.
  • R 2 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is halo (C 1 -C 4 ) alkyl or (C 1 -C 4 ) alkyl, wherein the remaining variables are as described above for Formula I or any one of the third to ninth embodiments.
  • R 2 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is (C 1 -C 4 ) alkyl, wherein the remaining variables are as described above for Formula I or any one of the third to ninth embodiments.
  • R 2 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is CH 3 , CH 2 CH 3 , CF 3 CH 2 , CF 3 , CH (CH 3 ) 2 , or CH 2 CH (CH 3 ) 2 , wherein the remaining variables are as described above for Formula I or any one of the third to ninth embodiments.
  • R 2 in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is CH 3 , wherein the remaining variables are as described above for Formula I or any one of the third to ninth embodiments.
  • X in the compound of Formula I or II, or a pharmaceutically acceptable salt thereof is SO 2 , wherein the remaining variables are as described above for Formula I or any one of the third to tenth embodiments.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile.
  • pharmaceutical compositions comprising crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile.
  • use of crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile for treating diseases responsive to the inhibition of PPARG.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile wherein the crystalline form is characterized by at least three x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, 18.8°, and 19.8°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by at least four x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, 18.8°, and 19.8°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, 18.8°, and 19.8°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, and 12.7°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, and 19.8°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by at least three x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, 17.7°, 18.8°, 19.8°, and 22.2°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by at least four x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, 17.7°, 18.8°, 19.8°, and 22.2°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by at least five x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, 17.7°, 18.8°, 19.8°, and 22.2°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by at least six x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, 17.7°, 18.8°, 19.8°, and 22.2°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by x-ray powder diffraction peaks at 2 ⁇ angles selected from 6.1°, 9.3°, 12.7°, 17.7°, 18.8°, 19.8°, and 22.2°.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by at least three, at least four, at least five, at least six, at least eight, at least nine, or at least 10 peaks selected from those in Table 1.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by an XRPD substantially similar to FIG. 1.
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by a Differential Scanning Calorimetry (DSC) with a endotherm at 304 °C (onset temperature) , wherein the crystalline form may also comprise XRPD peaks at 2 ⁇ angles selected from any of those described above.
  • DSC Differential Scanning Calorimetry
  • crystalline Form A of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile is characterized by a Differential Scanning Calorimetry (DSC) substantially similar to FIG. 2, wherein the crystalline Form 1 may also comprise XRPD peaks at 2 ⁇ angles selected from any of those described above.
  • DSC Differential Scanning Calorimetry
  • compounds of Formula I can be prepared by a process comprising: reacting a compound of Formula A:
  • L is a leaving group
  • the remaining variables are as described above for the compound of Formula I or any one of the third to ninth embodiments, with the corresponding sulfur nucleophile of XR 2 to form the compound of Formula I.
  • the leaving group in the twelfth embodiment is a halogen leaving group such as chloro.
  • the compound of Formula A is reacted with the sulfur nucleophile in the presence of a copper catalyst such as, e.g., a copper (I) catalyst (e.g. CuI) or copper (II) catalyst (e.g., Cu 2 O, Cu (OAc) 2 , CuBr, CuCl, and the like.
  • the compound of Formula A is reacted with the sulfur nucleophile in the presence of a copper ligand such as e.g., an organic base (e.g., proline, quinolone-8-ol, hydroxyproline, N-Me glylcine, and dimethyl glycine) .
  • a copper ligand such as e.g., an organic base (e.g., proline, quinolone-8-ol, hydroxyproline, N-Me glylcine, and dimethyl glycine) .
  • q and r are each 0 in the twelfth embodiment.
  • XR 2 in the twelfth embodiment is – S (O) 2 (C 1 -C 4 ) alkyl such as – S (O) 2 CH 3 .
  • the compound of Formula A is reacted with the sulfur nucleophile in the presence of an organic solvent such as polar aprotic solvent (e.g., DMSO, DMF, NMP and DMA) .
  • an organic solvent such as polar aprotic solvent (e.g., DMSO, DMF, NMP and DMA) .
  • the compound of Formula A is reacted with the sulfur nucleophile in the presence of a base such as K 3 PO 4 , K 2 CO 3 , NaHCO 3 , K 2 HPO 4 , Na 2 CO 3 , Na 3 PO 4 , Li 3 PO 4 , KOtBu and KHMDS.
  • the compound of Formula I in the twelfth embodiment is 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile.
  • the compound of Formula I in the twelfth embodiment is crystalline Form A 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile as defined by one or more of the XRPD peaks defined herein.
  • the base in the eleventh embodiment is an inorganic base such as LiOtBu, LiOH, NaOH, KOH and CsOH ⁇ H 2 O.
  • the compound having the Formula B the eleventh embodiment is reacted with the base in the presence of an organic solvent such as a polar aprotic solvent like THF, 2-MeTHF, CPME, dioxane, and NMP.
  • the base in the eleventh embodiment is LiOtBu.
  • the leaving group in the thirteenth embodiment is a halogen leaving group such as chloro.
  • q and r are each 0 in the thirteenth embodiment.
  • the compound of Formula A in the thirteenth embodiment is In some aspects, the compound of Formula B in the thirteenth embodiment, is
  • L is a leaving group such as a halogen leaving group (e.g., chloro)
  • halogen leaving group e.g., chloro
  • q and r are each 0 in the fourteenth embodiment.
  • the compound of Formula B in the fourteenth embodiment is In some aspects, the compound of Formula C in the fourteenth embodiment, is In some aspects, the compound of Formula D in the fourteenth embodiment, is wherein L is as defined above.
  • L v is a leaving group such as e.g., a halogen (e.g., fluoro) , with ammonia ion such as from ammonium hydroxide to form the compound having the Formula C.
  • the compound having the Formula E is reacted with ammonia ion such as from ammonium hydroxide in the presence of an organic solvent such as a polar aprotic or polar protic solvent like THF, 2-MeTHF, IPA, toluene, acetonitrile, DMP, NMP, CPME and MTBE.
  • the compound having the Formula E is reacted with ammonia ion such as from ammonium hydroxide in the presence of 2-MeTHF.
  • q and r are each 0 in the fifteenth embodiment.
  • the compound of Formula C in the fifteenth embodiment is In some aspects, the compound of Formula E in the fifteenth embodiment, is
  • L is a leaving group such as e.g., a halogen leaving group (e.g., chloro) and wherein the remaining variables are as described above for Formula I or any one of the fourth or fifth embodiments, said process comprising reacting a compound having the Formula F:
  • the compound of Formula D in the sixteenth embodiment is In some aspects, the compound of Formula F in the sixteenth embodiment, is
  • L is a leaving group such as a halogen leaving group (e.g., chloro) and R 4 is as described above for Formula I or any one of the fourth or fifth embodiments, said process comprising reacting a compound having the Formula H:
  • the process further comprises the addition of a palladium coupling ligand such as e.g., dppb, tBu 3 HBF 4 , dppp, Ph 3 P, XantPhos, dppf, AmgenPHOS, DPEPhos, RuPHOS, R-BINAP, (o-tol) 3 P, S-PHOS, X-Phos, tBu-XPhos, and Ph 2 -CH 2 CH 2 - (2-Pyr) ) .
  • Solvent DMAc, tBuOH, DMAc/water, and tBuOH/water.
  • the compound of Formula G in the seventeenth embodiment is In some aspects, the compound of Formula H in the seventeenth embodiment, is
  • the compounds and compositions described herein are generally useful for modulating the activity of PPARG.
  • the compounds, pharmaceutical acceptable salts, and pharmaceutical compositions described herein inhibit the activity PPARG.
  • the compounds and pharmaceutical acceptable salts disclosed herein are agonists of PPARG.
  • the compounds and pharmaceutical acceptable salts disclosed herein are agonists of PPARG.
  • the compounds and pharmaceutical acceptable salts disclosed herein are inverse agonists of PPARG.
  • inverse-agonists refer to agents that bind to the same receptor binding site as a agonist (e.g., the binding site of a nuclear receptor such as PPARG) and not only antagonizes the effects of an agonist but, moreover, exerts the opposite effect by suppressing spontaneous receptor signaling (when present) .
  • the compounds and pharmaceutical acceptable salts disclosed herein overcome the activated state of PPARG function resulting from alteration in PPARG activity (mutation, amplification or overexpression) or from RXRA activating mutations.
  • the compounds and pharmaceutical acceptable salts disclosed herein increase the repressive state (NCOR1 recruitment) to a higher degree than previously disclosed PPARG modulators such as prior inverse agonists. Such results even arise in the mutant context. See e.g., the table qualitatively assessing NCOR1 recruitment and repression of PPARG target genes in HT1197 in the Exemplification section.
  • the compounds and pharmaceutical compositions described herein are useful in treating a disorder associated with PPARG function.
  • methods of treating a disorder associated with PPARG function comprising administering to a subject in need thereof, a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a disclosed compound or pharmaceutically acceptable salt thereof.
  • a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a disclosed compound or pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a disorder associated with PPARG function.
  • the disorder associated with PPARG is cancer.
  • the cancer is associated with an up-regulated peroxisome proliferator-activated receptor (PPAR) signaling pathway.
  • PPAR peroxisome proliferator-activated receptor
  • the up-regulated PPAR signaling pathway is associated with increased expression of one or more genes selected from Uroplakin 1A (UPK1A) , Uroplakin IB (UPK1B) , Uroplakin (UPK2) , Keratin 20 (KRT20) , GATA Binding Protein 3 (GAT A3) , Nuclear Receptor Corepressor 1 (NCORl) , Nuclear Receptor Corepressor 2 (NCOR2) , Fatty Acid Binding Protein 4 (FABP4) , Forkhead Box Al (FOXA1) , CD36 Molecule (CD36) , Acyl-CoA Oxidase 1 (ACOX1) , 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 (H
  • the cancer treated by the compounds, pharmaceutically acceptable salt thereof, and pharmaceutical compositions described herein is selected from breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, renal cancer, bladder cancer, testicular cancer, urothelial cancer (e.g., non-muscle-invasive urothelial cancer, muscle-invasive urothelial cancer, metastatic urothelial cancer) , skin cancer, melanoma, colon cancer, kidney cancer, brain cancer and a hematopoietic cancer (e.g., lymphoma, multiple myeloma and leukemia) .
  • urothelial cancer e.g., non-muscle-invasive urothelial cancer, muscle-invasive urothelial cancer, metastatic urothelial cancer
  • skin cancer melanoma
  • colon cancer melanoma
  • kidney cancer melanoma
  • brain cancer a hematopoietic cancer
  • the cancer treated by the compounds, pharmaceutically acceptable salt thereof, and pharmaceutical compositions described herein is urothelial cancer such as non-muscle-invasive urothelial cancer, muscle-invasive urothelial cancer, and metastatic urothelial cancer.
  • cancer uses besides cancer and include e.g., metabolic diseases (e.g., osteoporosis, rachitis, arthrosis, obesity, type I and type II diabetes mellitus) , lipid metabolism disorder, pancreatitis, glucose metabolism disorder, diabetic neuropathy, diabetic complications, hyperuricemia, osteoporosis, rachitis, arthrosis inflammatory diseases (e.g., inflammatory skin diseases such as psoriasis, atopic dermatitis, eczema, acne vulgaris, other dermatitides and pruritus) , pulmonary disorders (e.g., asthma and chronic obstructive pulmonary disease) , autoimmune disease, neurodegenerative disease (e.g., multiple sclerosis, Alzheimer's disease, and Parkinson's disease) , cardiovascular diseases (e.g., selected from atherosclerosis, venous and arterial occlusive diseases) , restenosis after invasive procedures, cardiomyopathy, myocardial inflammatory diseases (
  • a pharmaceutical composition described herein is formulated for administration to a patient in need of such composition.
  • Pharmaceutical compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the pharmaceutical compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the pharmaceutical compositions are administered orally.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of a compound described herein in the composition will also depend upon the particular compound in the pharmaceutical composition.
  • XRPD samples were analyzed using a Bruker D8 ADVANCE X-ray diffractometer using copper radiation (Cu K ⁇ , ) .
  • the generator was operated at a voltage of 40 KV and an amperage of 40 mA. Data were collected with a scanning range of 4 to 40° with a step size of 0.02°, scanning speed of 10 °/minute and a sample rotation speed of 15 rpm.
  • Compounds of formula S2 may be prepared from the anilines S1 by treatment with acetonitrile, boron trichloride, aluminum trichloride and HCl in an organic solvent such as dichloromethane.
  • Treatment of the acetylaniline S2 with an acyl chloride S3 yields intermediates of formula S4.
  • Quinolones like S5 may then be prepared by treatment of S4 with a hydroxide base in an organic solvent such as dioxane at elevated temperature.
  • the chloride on S5 may then be replaced with sulfur-based nucleophiles to provide S6. via an SNAr reaction or via a copper catalysis.
  • Acyl chlorides S3 may be prepared from the corresponding acid by treatment with thionyl chloride or oxalyl chloride in an organic solvent such as dichloromethane.
  • Certain quinolone analogues S6 may also be prepared via a two-step process consisting of nucleophile addition of a thiol to S5 followed by oxidation of the thioether S7.
  • Certain quinolone analogues S6 may also be prepared a three-step process consisting of acylation of S2 with S8 to yield S9, cyclization amide S9 to yield quinolones S7, and oxidation of the thioether of S7.
  • Step 1 1- (3-bromo-2, 6-difluoro-4-nitrophenyl) -4-methylpiperazine: To a solution 2-bromo-3, 4, 5-trifluoro-1-nitrobenzene (5 g, 19.5 mmol, 1.0 eq) in DMSO (50 mL) was added K 2 CO 3 (4.05 g, 29.3 mmol, 1.5 eq) and 1-methylpiperazine (1.96 g, 19.5 mmol, 2.2 mL, 1.0 eq) . The mixture was stirred at 20°C for 16 hrs. LCMS showed compound 1 was consumed completely and one main peak with desired mass was detected.
  • Step 2 2-bromo-3, 5-difluoro-4- (4-methylpiperazin-1-yl) aniline: To a solution of 1- (3-bromo-2, 6-difluoro-4-nitrophenyl) -4-methylpiperazine (6.5 g, 19.3 mmol, 1.0 eq) in EtOH (40 mL) was added a solution of NH 4 Cl (5.17 g, 96.7 mmol, 5.0 eq) in H 2 O (20 mL) and Fe (5.40 g, 96.7 mmol, 5.0 eq) . The mixture was stirred at 80°C for 2 hrs. LCMS showed compound 2 was consumed completely and one main peak with desired mass was detected.
  • Step 3 1- (6-amino-2, 4-difluoro-3- (4-methylpiperazin-1-yl) phenyl) ethan-1-one: To a solution of tributyl (1-ethoxyvinyl) stannane (10.5 g, 29.0 mmol, 3.0 eq) and 2-bromo-3, 5-difluoro-4- (4-methylpiperazin-1-yl) aniline (3 g, 9.80 mmol, 1.0 eq) in toluene (30 mL) was added Pd (PPh 3 ) 4 (1.13 g, 980 umol, 0.1 eq) . The mixture was stirred at 120°C for 16 hrs.
  • Step 1 methyl 2-chloro-5-cyano-benzoate: To a solution of 2-chloro-5-cyano-benzoic acid (10 g, 55.0 mmol, 1.0 equiv. ) was added SOCl 2 (82.0 g, 689.2 mmol, 50 mL, 12.5 equiv. ) . The reaction mixture was stirred at 80 °C for 1 hour. The reaction mixture was cooled to RT and concentrated under reduced. The residue was dissolved in THF (50 mL) and added to MeOH (50 mL) .
  • Step 3 5-cyano-2- (methylthio) benzoyl chloride: A solution of 5-cyano-2- (methylthio) benzoic acid (4.2 g, 22.0 mmol, 1.0 equiv. ) in SOCl 2 (56 mL) was stirred at 80 °C for 1 hour. The mixture was concentrated under reduced pressure to afford the title compound (4.6 g, 99%yield) as a yellow solid. The product was used without further purification.
  • 2-chloro-5-cyanobenzoic acid 2-chloro-5-iodobenzoic acid (6.0 g, 21.2 mmol, 1.0 equiv. ) was combined with tert-butanol (18 g) , water (24 g) , potassium carbonate (2.94 g, 21.2 mmol, 1.0 equiv. ) , potassium ferrocyanide trihydrate (4.49 g, 10.6 mmol, 0.5 equiv. ) . The mixture was stirred for 1 hour before addition of tris (dibenzylideneacetone) dipalladium (0) (0.097 g, 0.1 mmol, 0.005 equiv.
  • the filtrate was extracted twice with methyl tert-butyl ether (2 x 18 g) and the aqueous layer was combined with ethyl acetate (54 g) and adjusted to 20 °C.
  • a 2N HCl solution (48 g) was added dropwise over 4 hours at 20 °C.
  • the mixture was stirred for one hour before the bottom aqueous layer was removed.
  • the organic layer was washed with water (30 g) and treated with activated carbon (0.2 g) for 5 hours before removal by filtration and rinsing with ethyl acetate (12 g) .
  • the filtrate was concentrated to 12 mL under vacuum before charging acetone (24 g) and the process repeated.
  • the solution was then concentrated to 12 mL before a final charge of acetone (12 g) .
  • the mixture was adjusted to 35 °C for 2 hours before charging 0.2N HCl (90 g) over 4 hours.
  • the mixture was aged an additional 3 hours at 35 °Cbefore adjusting to 25 °C over 5 hours and holding for 3 hours.
  • the slurry was filtered and washed with water (12 g) before drying at 50 °C to deliver the title compound (2.7 g, 71%yield) .
  • Toluene (30 g) was charged to the organic layer before washing twice with 3N HCl (2 x 30 g) and once with 5%aqueous NaHCO 3 (30 g) .
  • the organic layer was concentrated to 20 mL under vacuum before charging isopropyl acetate (80 g) .
  • the mixture was again concentrated to 20 mL and isopropyl acetate (30 g) was charged to deliver the title compound as a solution in isopropyl acetate (82%assay yield) .
  • Lithium tert-butoxide (1.4 g, 17.9 mmol, 1.2 equiv. ) was added to a mixture of N- (2-acetyl-3, 5-difluorophenyl) -2-chloro-5-cyanobenzamide (5.0 g, 14.9 mmol, 1.0 equiv. ) and 2-methyltetrahydrofuran (100 g) .
  • the mixture was adjusted to 75 °C for 22 hours before cooling to 20 °C.
  • Dimethyl sulfoxide (20 g) was charge and the mixture adjusted to 40 °C for 2 hours.
  • a 1N HCl solution (50 g) was slowly added and the mixture stirred for an additional 3 hours at 40 °C.
  • the mixture was cooled to 5 °C over 3 hours and stirred for an additional 16 hours.
  • the slurry was filtered and the solids washed twice with water (2 x 10 g) and twice with acetone (2 x 10 g) .
  • the wet solids were then slurry washed in acetone (40 g) at 50 °C for 3 hours before cooling to 5 °C and stirring for an additional 3 hours.
  • the slurry was filtered and the solids rinsed with acetone (10 g) .
  • the solids were dried at 55 °C to deliver the title compound (4.8 g, 80%yield)
  • the DSC curve is shown in FIG. 2 and indicated an endothermic transition with onset of about 304 °C.
  • step 2.3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- ( (2, 2, 2- trifluoroethyl) sulfonyl) -benzonitrile: To a mixture of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- ( (2, 2, 2-trifluoroethyl) thio) benzonitrile (100 mg, 252 ⁇ mol, 1 equiv.
  • step 2.3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- ( (2, 2, 2- trifluoroethyl) sulfinyl) benzonitrile:
  • step 1.3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylthio) benzonitrile:
  • step 2.3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfinyl) benzonitrile:
  • step 2.3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (S- methylsulfonimidoyl) benzonitrile:
  • Step 1 1- (2-amino-4-chlorophenyl) ethanone: To a solution of 1- (4-chloro-2-nitrophenyl) ethanone (35 g, 175 mmol, 1.0 equiv. ) in H 2 O (350 mL) and acetic acid (350 mL) was added iron (0) (39.1 g, 701 mmol, 4.0 equiv. ) . The mixture was stirred at 100 °C for 2 hours. The suspension was filtered through a pad of Celite and the filter cake was washed with ethyl acetate (3 x 100 ml) . The filtrate was concentrated under reduced pressure.
  • Step 2 N- (2-acetyl-5-chlorophenyl) -5-cyano-2- (methylthio) benzamide: To a solution of 1- (2-amino-4-chlorophenyl) ethenone (6.7 g, 39.6 mmol, 1.0 equiv. ) in isopropyl acetate (300 mL) was added 5-cyano-2-methylsulfanyl-benzoyl chloride (8.4 g, 39.6 mmol, 1.0 equiv. ) . The mixture was stirred at 80 °C for 6 hours. The mixture was cooled to RT and filtered. The filter cake was washed with ethyl acetate (500 mL) .
  • Step 4 3- (7-chloro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) - benzonitrile: To a solution of 3- (7-chloro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylthio) benzonitrile (5.0 g, 15.3 mmol, 1.0 equiv. ) in H 2 O (160 mL) , CHCl 3 (80 mL) , and acetonitrile (80 mL) was added NaIO 4 (9.8 g, 45.9 mmol, 3.0 equiv.
  • Step 1 1- (2-amino-4-chloro-6-fluorophenyl) ethanone: To a solution of 3-chloro-5-fluoroaniline (20 g, 137 mmol, 1.0 equiv. ) in p-xylene (40 mL) was added BCl 3 (1 M, 182.7 mL, 1.3 equiv. ) at 0-5 °C over 2 hours. The mixture was warmed up to RT within 0.5 hours and stirred at RT for 10 minutes. Then acetonitrile (57.8 mL, 1.10 mol, 8 equiv. ) was added dropwise at RT over 20 minutes.
  • Step 2 N- (2-acetyl-5-chloro-3-fluorophenyl) -5-cyano-2- (methylthio) benzamide: To a solution of 1- (2-amino-4-chloro-6-fluorophenyl) ethanone (4.1 g, 21.8 mmol, 1 equiv. ) in isopropyl acetate (48 mL) was added 5-cyano-2- (methylthio) benzoyl chloride (4.6 g, 21.8 mmol, 1.0 equiv. ) . The mixture was stirred at 80 °C for 2 hours. The mixture was cooled to RT and concentrated under reduced pressure.
  • Step 4 3- (7-chloro-5-fluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile: To a solution of 3- (7-chloro-5-fluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylthio) -benzonitrile (3.2 g, 9.2 mmol, 1.0 equiv. ) in acetone (16.8 mL) , H 2 O (9.6 mL) , THF (12 mL) and MeOH (12 mL) was added Oxone (28.5 g, 46.4 mmol, 5.0 equiv. ) .
  • Step 1 methyl 5-cyano-2-iodo-benzoate: To a solution of 5-cyano-2-iodo-benzoic acid (4.0 g, 14.6 mmol, 1.0 equiv. ) in MeOH (30 mL) was added H 2 SO 4 (1.2 mL, 22.8 mmol, 1.6 equiv. ) . The mixture was stirred at 80 °C for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with water (30 mL) and extracted with ethyl acetate (3 x 30 mL) .
  • Step 2 Methyl 5-cyano-2- (trifluoromethylsulfanyl) benzoate: To a mixture of methyl 5-cyano-2-iodo-benzoate (1.5 g, 5.2 mmol, 1.0 equiv. ) and trifluoromethylsulfanylsilver (1.1 g, 5.2 mmol, 1.0 equiv. ) in DMF (15 mL) was added copper (I) bromide (75.0 mg, 523 ⁇ mol, 0.1 equiv. ) and 1, 10-phenanthroline (188.3 mg, 1.1 mmol, 0.2 equiv. ) at RT under N 2 . The mixture was stirred at 80 °C for 16 hours under N 2 .
  • Step 4 N- (2-acetyl-3, 5-difluoro-phenyl) -5 -cyano-2- (trifluoromethylsulfanyl) benzamide: SOCl 2 (5 mL) was added to a flask containing 5-cyano-2- (trifluoromethylsulfanyl) benzoic acid (1.0 g, 4.1 mmol, 1.0 equiv. ) at RT under N 2 . The mixture was stirred at 80 °Cfor 2 hours. The mixture was concentrated under reduced pressure to afford 5-cyano-2- (trifluoromethylsulfanyl) benzoyl chloride (1.1 g, crude) as white solid which was used in the next phase of the reaction without further purification.
  • Step 5 3- (5, 7-difluoro-4-oxo-1H-quinolin-2-yl) -4- (trifluoromethylsulfanyl) benzonitrile: To a mixture of N- (2-acetyl-3, 5-difluoro-phenyl) -5-cyano-2- (trifluoromethylsulfanyl) benzamide (1.2 g, 3.0 mmol, 1.0 equiv. ) in 2-MeTHF (18 mL) was added LiOH (71.8 mg, 3.0 mmol, 1.0 equiv. ) in at RT under N 2 . The mixture was stirred at 80 °C for 32 hours under N 2 .
  • the reaction mixture was diluted with water (10 mL) and then concentrated to remove 2-MeTHF.
  • the precipitate that formed during the pH adjustment was filtered off and then triturated with acetonitrile at RT for 30 minutes to afford the title compound (930 mg, 80%yield) as a white solid.
  • LCMS [M+1] 383.0.
  • Step 6 3- (5, 7-difluoro-4-oxo-1H-quinolin -2-yl) -4- (trifluoromethylsulfonyl) benzonitrile: To a mixture of 3- (5, 7-difluoro-4-oxo-1H-quinolin-2-yl) -4- (trifluoromethylsulfanyl) benzonitrile (700 mg, 1.8 mmol, 1.0 equiv. ) and RuCl 3 (38 mg, 183.1 ⁇ mol, 0.1 equiv.
  • Step 1 5-cyano-2-isopropylsulfanyl-benzoic acid: To a solution of propane-2-thiol (2.3 mL, 25.5 mmol, 2.5 equiv. ) in DMF (20 mL) was added NaH (1.0 g, 25.5 mmol, 2.5 equiv.; 60%dispersion in oil) . The reaction mixture was stirred at RT for 1 hour before methyl 2-chloro-5-cyano-benzoate (2.0 g, 10.2 mmol, 1.0 equiv. ) was added to the mixture. The resulting mixture was stirred at RT for 2 hours. The reaction was quenched with H 2 O (2 equiv.
  • Step 2 N- (2-acetyl-3, 5-difluoro-phenyl) -5-cyano-2-isopropylsulfanyl-benzamide: A solution of 5-cyano-2-isopropylsulfanyl-benzoic acid (500 mg, 2.2 mmol, 1.0 equiv. ) in SOCl 2 (5.0 mL) was stirred at 80 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to afford 5-cyano-2-isopropylsulfanyl-benzoyl chloride (542 mg, crude) as a yellow solid. This material was used in the next phase of the reaction without further purification.
  • Step 4 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (isopropylsulfonyl) benzonitrile: To a solution of 3- (5, 7-difluoro-4-oxo-1H-quinolin-2-yl) -4-isopropylsulfanyl-benzonitrile (150 mg, 421 ⁇ mol, 1.0 equiv. ) in DCM (5.0 mL) was added m-CPBA (256 mg, 1.2 mmol, 3.0 equiv.; 85%purity) . The reaction mixture was stirred at RT for 16 hours.
  • m-CPBA 256 mg, 1.2 mmol, 3.0 equiv.; 85%purity
  • Step 1 1- [6-amino-2, 4-difluoro-3- (1-methylpyrazol-4-yl) phenyl] ethenone: To a solution of 1-methyl-4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrazole (500 mg, 2.4 mmol, 1.0 equiv. ) and 1- (6-amino-2, 4-difluoro-3-iodo-phenyl) ethanone (714 mg, 2.4 mmol, 1.0 equiv. ) in dioxane (7.5 mL) was added a solution of K 2 CO 3 (664 mg, 4.8 mmol, 2.0 equiv.
  • Step 2 N- [2-acetyl-3, 5-difluoro-4- (1-methylpyrazol-4-yl) phenyl] -2-chloro-5- cyano-benzamide: To a mixture of 1- [6-amino-2, 4-difluoro-3- (1-methylpyrazol-4-yl) phenyl] ethanone (200 mg, 796 ⁇ mol, 1.0 equiv. ) in isopropyl acetate (1.5 mL) was added 2-chloro-5-cyano-benzoyl chloride (195 mg, 876 ⁇ mol, 1.1 equiv. ) at RT under N 2 . The mixture was stirred at 80° C for 8 hours.
  • Step 3 4-chloro-3- [5, 7-difluoro-6- (1-methylpyrazol-4-yl) -4-oxo-1H-quinolin-2- yl] benzonitrile: To a mixture of N- [2-acetyl-3, 5-difluoro-4- (1-methylpyrazol-4-yl) phenyl] -2-chloro-5-cyano-benzamide (300 mg, 723 ⁇ mol, 1.0 equiv. ) in dioxane (1 mL) was added LiOH (19.0 mg, 796 ⁇ mol, 1.1 equiv. ) at RT under N 2 . The mixture was stirred at 110 °C for 12 hours.
  • Step 4 3- [5, 7-difluoro-6- (1-methylpyrazol-4-yl) -4-oxo-1H-quinolin -2-yl] -4- methylsulfonyl-benzonitrile: To a mixture of sodium methanesulfinate (37.0 mg, 363 ⁇ mol, 1.2 equiv. ) , 4-chloro-3- [5, 7-difluoro-6- (1-methylpyrazol-4-yl) -4-oxo-1H-quinolin-2-yl] benzonitrile (120 mg, 302 ⁇ mol, 1.0 equiv. ) and K 3 PO 4 (96.3 mg, 453.7 ⁇ mol, 1.5 equiv.
  • TR-FRET binding assay measuring association of a biotinylated NCOR1 ID2 peptide (Biotin-GHSFADPASNLGLEDIIRKALMG-amide) to PPARG/RXRA LBD heterodimer.
  • a 20 microliters of TR-FRET master mix consisting of 2 nM WT PPARG LBD (e. coli expressed, His-TEV-Q203-Y477; Uniprot ID P37231-2) , 2 nM WT RXRA LBD or mutant S427F RXRA LBD (e.
  • TR-FRET ratios were normalized to the average ratio of DMSO control wells (0%) and to the average maximum ratio for positive control compound (T0070907 (2-chloro-5-nitro-N-4-pyridinyl-benzamide) ; defined as 100%) in CDD Vault and analyzed using the Levenberg-Marquardt algorithm.
  • TR-FRET binding assay measuring association of a biotinylated MED1 LxxLL peptide (Biotin-VSSMAGNTKNHPMLMNLLKDNPAQ-amide) to PPARG/RXRA LBD heterodimer.
  • a 20 microliters of TR-FRET master mix consisting of 2 nM WT PPARG LBD (e. coli expressed, His-TEV-Q203-Y477; Uniprot ID P37231-2) , 2 nM WT RXRA LBD (e.
  • TR-FRET ratios were normalized to the average ratio of DMSO control wells (0%) and to the average minimum ratio for positive control compound (GW9662 (2-chloro-5-nitrobenzanilide) ; defined as 100%) in CDD Vault and analyzed using the Levenberg-Marquardt algorithm.
  • the EC 50 is expressed as follows, A: ⁇ 10 nM, B: 10-100 nM, C: 100-1,000 nM, D: 1,000-10,000 nM, E: >10,000 nM.
  • the %NCOR recruitment is expressed as follows, A: >100% (> the control compound, T907) , B: ⁇ 100% ( ⁇ the control compound, T907) .
  • the EC 50 is expressed as follows, A: ⁇ 10 nM, B: 10-100 nM, C: 100-1,000 nM, D: 1,000-10,000 nM, E: >10,000 nM.
  • the %MED1 blockade is expressed as follows, A: >100% (> the control compound, GW9662) , B: ⁇ 100% ( ⁇ the control compound, GW9662) .
  • the EC 50 is expressed as follows, A: ⁇ 10 nM, B: 10-100 nM, C: 100-1,000 nM, D: 1,000-10,000 nM, E: >10,000 nM, ND: not determined.
  • the %inhibition of ANGPTL4, a PPARG target gene, at 100 nM compound concentration is expressed as percentage of a DMSO control experiment.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/CN2022/129034 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof Ceased WO2023078252A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
EP25188854.1A EP4653053A1 (en) 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof
AU2022380979A AU2022380979A1 (en) 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof
FIEP22809321.7T FI4426434T3 (fi) 2021-11-02 2022-11-01 Pparg:n käänteisagonisteja ja niiden käyttöjä
MDE20240849T MD4426434T2 (ro) 2021-11-02 2022-11-01 Agonişti inverși PPARG şi utilizările acestora
CA3237199A CA3237199A1 (en) 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof
KR1020247017817A KR20240144096A (ko) 2021-11-02 2022-11-01 Pparg 역 효능제 및 그의 용도
CN202280086503.8A CN119677720A (zh) 2021-11-02 2022-11-01 Pparg反向激动剂及其用途
ES22809321T ES3053082T3 (en) 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof
PL22809321.7T PL4426434T3 (pl) 2021-11-02 2022-11-01 Odwrotne agonisty pparg i ich zastosowania
LTEPPCT/CN2022/129034T LT4426434T (lt) 2021-11-02 2022-11-01 Pparg atvirkštiniai agonistai ir jų paskirtys
EP22809321.7A EP4426434B1 (en) 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof
IL312547A IL312547A (en) 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof
MA67105A MA67105B1 (fr) 2021-11-02 2022-11-01 Agonistes inverses de pparg et leurs utilisations
DK22809321.7T DK4426434T3 (da) 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof
HRP20251438TT HRP20251438T1 (hr) 2021-11-02 2022-11-01 Inverzni agonisti pparg i njihova upotreba
PE2024000994A PE20250739A1 (es) 2021-11-02 2022-11-01 Agonistas inversos del pparg y usos de los mismos
SI202230204T SI4426434T1 (sl) 2021-11-02 2022-11-01 Inverzni agonisti PPARG in njihova uporaba
SM20250447T SMT202500447T1 (it) 2021-11-02 2022-11-01 Agonisti inversi di pparg e loro usi
RS20251169A RS67425B1 (sr) 2021-11-02 2022-11-01 Inverzni agonisti pparg i njihove upotrebe
JP2024526592A JP2025508272A (ja) 2021-11-02 2022-11-01 Pparg逆アゴニストおよびその使用
US18/130,121 US11820747B2 (en) 2021-11-02 2023-04-03 PPARG inverse agonists and uses thereof
MX2024005405A MX2024005405A (es) 2021-11-02 2024-05-02 Agonistas inversos del receptor activado por el proliferador de peroxisomas gamma (pparg) y usos de los mismos
US18/664,492 US20250084038A1 (en) 2021-11-02 2024-05-15 Pparg inverse agonists and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163274596P 2021-11-02 2021-11-02
US63/274,596 2021-11-02
US202263347671P 2022-06-01 2022-06-01
US63/347,671 2022-06-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/130,121 Continuation US11820747B2 (en) 2021-11-02 2023-04-03 PPARG inverse agonists and uses thereof

Publications (1)

Publication Number Publication Date
WO2023078252A1 true WO2023078252A1 (en) 2023-05-11

Family

ID=84283142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/129034 Ceased WO2023078252A1 (en) 2021-11-02 2022-11-01 Pparg inverse agonists and uses thereof

Country Status (25)

Country Link
US (2) US11820747B2 (cg-RX-API-DMAC7.html)
EP (2) EP4426434B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508272A (cg-RX-API-DMAC7.html)
KR (1) KR20240144096A (cg-RX-API-DMAC7.html)
CN (1) CN119677720A (cg-RX-API-DMAC7.html)
AU (1) AU2022380979A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237199A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001346A1 (cg-RX-API-DMAC7.html)
DK (1) DK4426434T3 (cg-RX-API-DMAC7.html)
ES (1) ES3053082T3 (cg-RX-API-DMAC7.html)
FI (1) FI4426434T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251438T1 (cg-RX-API-DMAC7.html)
IL (1) IL312547A (cg-RX-API-DMAC7.html)
LT (1) LT4426434T (cg-RX-API-DMAC7.html)
MA (1) MA67105B1 (cg-RX-API-DMAC7.html)
MD (1) MD4426434T2 (cg-RX-API-DMAC7.html)
MX (1) MX2024005405A (cg-RX-API-DMAC7.html)
PE (1) PE20250739A1 (cg-RX-API-DMAC7.html)
PL (1) PL4426434T3 (cg-RX-API-DMAC7.html)
PT (1) PT4426434T (cg-RX-API-DMAC7.html)
RS (1) RS67425B1 (cg-RX-API-DMAC7.html)
SI (1) SI4426434T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500447T1 (cg-RX-API-DMAC7.html)
TW (1) TW202334089A (cg-RX-API-DMAC7.html)
WO (1) WO2023078252A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024221455A1 (en) * 2023-04-28 2024-10-31 Flare Therapeutics, Inc. Crystalline forms of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile
EP4489863A1 (en) * 2022-03-08 2025-01-15 Flare Therapeutics, Inc. Pparg inverse agonists and uses thereof
WO2025090706A1 (en) 2023-10-27 2025-05-01 Flare Therapeutics Inc. Pparg inverse agonists and immunotherapies for treating cancer
WO2025098515A1 (en) * 2023-11-10 2025-05-15 Danatlas Pharmaceuticals Co., Ltd. Heterocyclic derivatives, compositions and uses thereof
WO2026046259A1 (zh) * 2024-08-27 2026-03-05 杭州英创医药科技有限公司 作为pparg反向激动剂的化合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7853310B2 (ja) * 2021-03-02 2026-04-28 フレア・セラピューティクス・インコーポレーテッド Pparg逆アゴニストおよびその使用
SMT202500447T1 (it) * 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028427A1 (en) * 2006-09-04 2008-03-13 Univerzita Palackeho Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization
CN105982884B (zh) * 2015-02-25 2019-05-24 上海中医药大学 一种补骨脂二氢黄酮甲醚及其类似物的用途
WO2019246343A1 (en) * 2018-06-21 2019-12-26 Taiwanj Pharmaceuticals Co., Ltd. Nadph oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof
CN107522657B (zh) * 2017-09-28 2020-06-26 上海中医药大学 一种具有ppar多重激动活性的化合物及其制备方法和应用

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT302033B (de) 1968-08-22 1972-09-25 Agfa Gevaert Ag Photographisches Material
JPS58219166A (ja) 1982-06-14 1983-12-20 Nippon Shinyaku Co Ltd 4−キノロン誘導体
JPS604170A (ja) 1983-06-21 1985-01-10 Nippon Shinyaku Co Ltd キノロン誘導体
FR2594438B1 (fr) 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US4992464A (en) 1987-02-10 1991-02-12 Abbott Laboratories Heteroaryl N-hydroxy amides and ureas with polar substituents as 5-lipoxygenase inhibitors
IL87181A (en) 1987-08-07 1993-08-18 Sanofi Sa Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
FR2636327A1 (fr) 1988-09-13 1990-03-16 Rhone Poulenc Sante Derives de quinoleine, leurs procedes de preparation et les medicaments les contenant
ATE117294T1 (de) 1989-08-11 1995-02-15 Ici Plc Chinolin-derivate, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
IE903911A1 (en) 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
GB9017482D0 (en) 1990-08-09 1990-09-26 Ici Plc Manufacturing process
GB9017480D0 (en) 1990-08-09 1990-09-26 Ici Plc Chemical process
GB9025123D0 (en) 1990-11-19 1991-01-02 Ici Plc Nitrogen compounds
TW274551B (cg-RX-API-DMAC7.html) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
GB9113626D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
GB9121727D0 (en) 1991-10-14 1991-11-27 Ici Plc Heterocyclic compounds
HRP930210A2 (en) 1992-02-25 1995-06-30 Recordati Chem Pharm Heterobicyclic compounds and pharmaceutical preparations containing them
US5605896A (en) 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IL105357A (en) 1992-04-30 1997-07-13 Basf Ag Benzyl enol ethers and benzyloxy carbocyclic and heterocyclic derivatives thereof and their use as crop protection agents
GB9211292D0 (en) 1992-05-28 1992-07-15 Ici Plc Heteroecyclic compounds
AU4348593A (en) 1992-06-25 1994-01-24 Zeneca Limited Chromanderivatives as angiotensin ii antagonists
US5663179A (en) 1992-07-10 1997-09-02 Laboratoires Glaxo Sa Certain isoquinoline derivatives having anti-tumor properties
WO1994002145A2 (en) 1992-07-22 1994-02-03 Genelabs Technologies, Inc. 2-aryl-4-quinolones as antitumor compounds
JPH0673047A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd キノロン誘導体
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5622821A (en) 1994-06-29 1997-04-22 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
US5571822A (en) 1994-09-30 1996-11-05 The University Of North Carolina At Chapel Hill Antitumor compounds
JPH08301849A (ja) 1995-05-01 1996-11-19 Takeda Chem Ind Ltd ヘテロ環化合物およびその製造法
WO1996041800A1 (en) 1995-06-12 1996-12-27 Chavunduka, Gordon, Lloyd Isolation of naturally occurring isoflavanone and some clinical uses thereof
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
JPH09202774A (ja) 1996-01-25 1997-08-05 Green Cross Corp:The 2−アリールキノリン類およびその製造方法
US6080757A (en) 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
US5942508A (en) 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
US6274592B1 (en) 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6306856B1 (en) 1998-09-18 2001-10-23 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid, solubilizer therefor, aqueous solution preparation containing pyridonecarboxylic acid and process for producing the same
AU4171600A (en) 1999-03-09 2000-09-28 Arqule, Inc. Lanthanide catalysts for synthesis of compounds and combinatorial libraries
MY138338A (en) 1999-04-07 2009-05-29 Inst For Pharm Discovery Inc Substituted indolealkanoic acids
SK9532002A3 (en) 1999-12-31 2003-06-03 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001081340A2 (en) 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
AU2001255696A1 (en) 2000-04-27 2001-11-07 Geron Corporation Telomerase inhibitors and methods of their use
US6521030B1 (en) 2000-06-20 2003-02-18 Hewlett-Packard Company Inkjet ink sets with high ligthfastness dye
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
EP1307191A2 (en) 2000-07-28 2003-05-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
US6624317B1 (en) 2000-09-25 2003-09-23 The University Of North Carolina At Chapel Hill Taxoid conjugates as antimitotic and antitumor agents
US6569870B1 (en) 2000-09-25 2003-05-27 The University Of North Carolina At Chapel Hill Fluorinated quinolones as antimitotic and antitumor agents
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
US20040116497A1 (en) 2001-01-26 2004-06-17 Gabriella Traquandi Chromane derivatives, process for their preparation and their use as antitumor agents
JP2005520782A (ja) 2001-07-12 2005-07-14 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 向上した水溶解度を有するアミド含有化合物およびアミド含有化合物の水溶解度を向上させる方法
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
JP2005504770A (ja) 2001-08-17 2005-02-17 メルク エンド カムパニー インコーポレーテッド 5−スルホンアミド−8−ヒドロキシ−1,6−ナフチリジン−7−カルボキサミドの製造方法
AUPR870501A0 (en) 2001-11-07 2001-11-29 Biotech Research Ventures Pte Limited Composition containing a flavonoid glycone and method for using same as anti-proliferative
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US20030229136A1 (en) 2002-04-18 2003-12-11 Nurulain Zaveri Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents
WO2003094928A1 (en) 2002-05-06 2003-11-20 Diakron Pharmaceuticals, Inc. Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels
KR20050033052A (ko) 2002-07-01 2005-04-08 메르크 파텐트 게엠베하 중합가능한 발광성 화합물 및 혼합물, 발광성 중합체 물질및 이들의 용도
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
MXPA05003477A (es) 2002-10-03 2005-07-22 Targegen Inc Agentes vasculo-estaticos y metodos de uso de los mismos.
ES2440217T3 (es) 2002-10-04 2014-01-28 Prana Biotechnology Limited Compuestos neurológicamente activos
JP2006505559A (ja) 2002-10-18 2006-02-16 エフ.ホフマン−ラ ロシュ アーゲー 5−ht6受容体親和性を持つ4−ピペラジニルベンゼンスルホニルインドール
AU2003296984A1 (en) 2002-12-13 2004-07-09 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
JP2004244362A (ja) 2003-02-13 2004-09-02 Central Glass Co Ltd 1,2−ジ置換−1,4−ジヒドロ−オキソキノリン誘導体の製造方法
US6916831B2 (en) 2003-02-24 2005-07-12 The University Of North Carolina At Chapel Hill Flavone acetic acid analogs and methods of use thereof
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2004105779A2 (en) 2003-05-27 2004-12-09 Cesare Montecucco Green tea and oplyphenol inhibitors of bacterial proteases
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050096256A1 (en) 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US6897316B2 (en) 2003-08-08 2005-05-24 China Medical University Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents
JP2005078888A (ja) 2003-08-29 2005-03-24 Konica Minolta Holdings Inc 光電変換材料用半導体、光電変換素子及び太陽電池
JP4655460B2 (ja) 2003-09-02 2011-03-23 コニカミノルタホールディングス株式会社 光電変換材料用半導体、光電変換素子及び太陽電池
EP1678173A2 (en) 2003-09-09 2006-07-12 Neurogen Corporation 4-heterobicyclylamino-substituted quinazolines and analogues thereof as capsaicin-antagonists
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
JP2007509035A (ja) 2003-10-10 2007-04-12 レスバーロジックス コーポレイション Egr−1エンハンサー要素に関連する疾患の処置
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
CA2540460A1 (en) 2003-10-28 2005-05-12 Reddy Us Therapeutics, Inc. Heterocyclic compounds and methods of making and using thereof
JP2005162657A (ja) 2003-12-02 2005-06-23 Takeda Chem Ind Ltd カンナビノイド受容体調節剤
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
CA2551524A1 (en) 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with tgf-beta inhibitors
WO2005087227A1 (en) 2004-03-04 2005-09-22 Neurogen Corporation Arylalkylamino-substituted quinazoline analogues
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
KR20070020036A (ko) 2004-05-18 2007-02-16 브라이트 퓨처 파마수티컬 라보라토리스 리미티드 수면 장애를 위한 조성물
WO2006004722A2 (en) 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
EP1632491A1 (en) 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
JP2006096687A (ja) 2004-09-28 2006-04-13 Riron Soyaku Kenkyusho:Kk グリオキサラーゼi活性を阻害するアポトーシス誘導剤
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20090264384A1 (en) 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
AU2006204699B2 (en) 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006078891A2 (en) 2005-01-21 2006-07-27 Neurogen Corporation Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives
EP1865775A1 (en) 2005-04-06 2007-12-19 Irm, Llc Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
WO2007002781A2 (en) 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007042325A1 (de) 2005-10-13 2007-04-19 Morphochem Aktiengesellschaft für kombinatorische Chemie 5-chinolinderivate mit antibakterieller aktivität
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2007070986A1 (en) 2005-12-23 2007-06-28 Ecobiotics Limited Flavones
CN100516067C (zh) 2006-01-10 2009-07-22 上海恒瑞医药有限公司 具有抗肿瘤活性的紫杉酚衍生物
KR100784485B1 (ko) 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
JP2007230145A (ja) 2006-03-02 2007-09-13 Mitsubishi Chemicals Corp 光学記録媒体の記録層形成用色素、及びそれを用いた光学記録媒体、その光学記録媒体の記録方法
AU2007225088B2 (en) 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
AR059270A1 (es) 2006-03-24 2008-03-19 Olivera Nappa Alvaro Maria Formulaciones y metodos para dar valor agregado a productos vegetales aumentando la calidad comercial resistencia a factores externos y contenido de polifenoles de los mismos
US8097644B2 (en) 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
KR101325062B1 (ko) 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자
JP5415942B2 (ja) 2006-06-22 2014-02-12 プラナ バイオテクノロジー リミティッド 処置の方法およびその処置に有用な薬剤
JP2009541423A (ja) 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と5‐ht6レセプター親和性の化合物との組合せ
EP2079724B1 (en) 2006-07-20 2010-05-26 Amgen Inc. Substituted pyridone compounds and methods of use
JP2010500330A (ja) 2006-08-10 2010-01-07 フエルレル インターナショナル,ソシエダッド アノニマ Gabaa受容体に対して親和性を有する1h−キノリン−4−オン化合物、方法、使用及び組成物
EP1902733A1 (en) 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
AU2007319209B2 (en) 2006-11-15 2012-04-19 Genentech, Inc. Arylsulfonamide compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
EP2468747B1 (en) 2006-12-07 2014-09-03 China Medical University 2-Selenophene-4-quinolones as anticancer agents
WO2008073957A2 (en) 2006-12-12 2008-06-19 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US20080161247A1 (en) 2006-12-20 2008-07-03 National Institute Of Immunology And Indian Institute Of Science Synergistic composition for modulating activity of substrate analogs for NAD+, NADP+, NADH or NADPH dependent enzymes and process thereof
WO2008089439A2 (en) 2007-01-18 2008-07-24 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
WO2008116029A1 (en) 2007-03-19 2008-09-25 Wisconsin Alumni Research Foundation Modulation of bacterial quorum sensing with synthetic ligands
EP2171478A4 (en) 2007-03-30 2013-01-30 Univ California IN VIVO IMAGING METHOD FOR SULPHOTRANSFERASES
US20080261898A1 (en) 2007-04-17 2008-10-23 Liao Heather H Composition and method for cancer treatment and prevention
US8563594B2 (en) 2007-05-08 2013-10-22 Allergan, Inc. S1P3 receptor inhibitors for treating pain
EP2481735A1 (en) 2007-05-09 2012-08-01 Pfizer Inc. Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
US8759348B2 (en) 2007-05-17 2014-06-24 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009018219A2 (en) 2007-07-28 2009-02-05 University Of Chicago Methods and compositions for modulating rad51 and homologous recombination
EP2195308A2 (en) 2007-08-17 2010-06-16 Herbalscience Group LLC Antiinfective flavononol compounds and methods of use thereof
WO2009040377A2 (en) 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
GB0719751D0 (en) 2007-10-10 2007-11-21 Antoxis Ltd In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells
CN101444499B (zh) 2007-11-26 2012-12-05 湘北威尔曼制药股份有限公司 一种化合物及其组合物的新用途
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2599763A1 (en) 2008-02-14 2013-06-05 Siemens Molecular Imaging, Inc. Novel imaging agents for detecting neurological dysfunction
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
JP2011514385A (ja) 2008-03-17 2011-05-06 アラーガン、インコーポレイテッド 炎症を処置するためのs1p3受容体阻害剤
MX2010011168A (es) 2008-04-15 2010-12-21 Pharmacyclics Inc Inhibidores selectivos de histona-desacetilasa.
EP2262366A4 (en) 2008-04-18 2012-02-22 Shenogen Pharma Group Ltd COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
WO2010011836A2 (en) 2008-07-25 2010-01-28 Emory University Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
MX2011001851A (es) 2008-08-22 2011-03-21 Syngenta Participations Ag Compuestos insecticidas.
CN101357902B (zh) 2008-09-04 2011-06-29 浙江工业大学 一种n-甲酰基-2h-4-氯喹啉衍生物的制备方法
WO2010026771A1 (ja) 2008-09-08 2010-03-11 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
KR20100046905A (ko) 2008-10-28 2010-05-07 덕성여자대학교 산학협력단 2-아릴-4-퀴놀론 유도체의 제조 방법
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
EP2387575B1 (en) 2009-01-15 2013-09-04 Anvyl, LLC Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
JP2012520887A (ja) 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
US8969342B2 (en) 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
WO2010129553A1 (en) 2009-05-05 2010-11-11 Allergan, Inc. S1p3 receptor inhibitors for treating conditions of the eye
CA2781865A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
EP2470174A1 (en) 2009-08-27 2012-07-04 Merck Patent GmbH Use of faa and its derivatives in cosmetics and dermatology
WO2011054433A1 (en) 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
FR2956816B1 (fr) 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
CA3034600C (en) 2010-05-07 2020-11-10 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
CZ304527B6 (cs) 2010-06-16 2014-06-18 Univerzita PalackĂ©ho v Olomouci Deriváty 2-fenyl-3-hydroxychinolin-4(1H)-on-8-karboxamidů a způsob jejich přípravy a použití
MX2012015135A (es) 2010-07-01 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
JP2013533884A (ja) 2010-07-02 2013-08-29 アムジエン・インコーポレーテツド Pi3k活性阻害剤としての複素環化合物およびそれらの使用
US8524740B2 (en) 2010-07-15 2013-09-03 Tairx, Inc. Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
CN103153096B (zh) 2010-08-12 2016-08-03 赛诺米克斯公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US8558011B2 (en) 2010-08-31 2013-10-15 Janssen Pharmaceutica, Nv Cold menthol receptor-1 antagonists
GB201020076D0 (en) 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
WO2012083866A1 (en) 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
AU2012265219B2 (en) 2011-05-31 2017-02-16 Merck Patent Gmbh Compounds containing hydrido-tricyano-borate anions
JP2014522570A (ja) 2011-05-31 2014-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 電解質配合物
US20140094465A1 (en) 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
EP3345901A3 (en) 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
EP2726601B1 (en) 2011-06-29 2018-12-26 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US9282738B2 (en) 2011-07-11 2016-03-15 Wisconsin Alumni Research Foundation Antimicrobial compositions and methods of use thereof
WO2013010869A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
WO2013020184A1 (en) 2011-08-11 2013-02-14 Neuprotect Pty Ltd Flavonoid compounds, and methods of use thereof
JP2014528410A (ja) 2011-09-30 2014-10-27 キネタ・インコーポレイテツド 抗ウイルス化合物
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101821256B1 (ko) 2011-11-03 2018-01-24 삼성디스플레이 주식회사 헤테로고리 화합물 및 이를 포함하는 유기 전계 발광 소자
CN103183674B (zh) 2011-12-31 2017-09-12 江苏先声药业有限公司 一类稠杂环衍生物及其应用
DK2820006T3 (da) 2012-02-29 2017-11-06 Chemocentryx Inc Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister
JP6285352B2 (ja) 2012-03-26 2018-02-28 飯沼 宗和 3−デセン酸誘導体およびその用途
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
CN102675200B (zh) 2012-05-16 2014-04-09 中国药科大学 一类具有抗肿瘤活性的2-苯基-4-喹诺酮化合物、其制备方法及用途
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
KR20150028999A (ko) 2012-06-27 2015-03-17 에프. 호프만-라 로슈 아게 5-아자인다졸 화합물 및 이의 사용 방법
CN104487429B (zh) * 2012-07-27 2017-07-14 爱默蕾大学 杂环黄酮衍生物、组合物及与其相关的方法
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
EP3369730B1 (en) 2012-11-05 2020-08-05 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014087165A1 (en) 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
CN103880707B (zh) 2012-12-19 2016-04-13 上海交通大学医学院 Stat3小分子抑制剂及其应用
CN103877078B (zh) 2012-12-20 2017-03-15 上海交通大学医学院 Senp2小分子抑制剂及其应用
CN103961348B (zh) 2013-02-05 2016-08-17 上海交通大学医学院 Senp1小分子抑制剂及其应用
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
TW201542538A (zh) 2013-07-16 2015-11-16 奇尼塔公司 抗病毒化合物、醫藥組合物及其使用方法
WO2015031608A1 (en) 2013-08-28 2015-03-05 Vanderbilt University Substituted indole mcl-1 inhibitors
WO2015031613A1 (en) 2013-08-30 2015-03-05 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
EP3041470A4 (en) 2013-09-04 2017-05-03 Board Of Regents Of the University Of Texas System Methods and compositions for selective and targeted cancer therapy
US9815797B2 (en) 2013-12-09 2017-11-14 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
US9512092B2 (en) 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
CN104725363B (zh) 2013-12-20 2019-03-01 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
CN104744435B (zh) 2013-12-25 2017-03-01 上海医药工业研究院 喹啉类化合物、其盐、其中间体、制备方法及应用
WO2015169180A1 (en) 2014-05-04 2015-11-12 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods and use thereof
EP3140274A1 (en) 2014-05-09 2017-03-15 Sloan-kettering Institute For Cancer Research Naphthaquinone methyltransferase inhibitors and uses thereof
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 新規ナフチリジン及びイソキノリンならびにcdk8/19阻害剤としてのその使用
US20190284149A1 (en) 2014-09-12 2019-09-19 Ariagen, Inc. Aryl hydrocarbon receptor modulator
WO2016050921A1 (en) 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
WO2016094730A1 (en) 2014-12-12 2016-06-16 Synereca Pharmaceuticals, Inc. Heterocyclic compounds as antibiotic potentiators
CN105732591B (zh) 2014-12-31 2019-10-25 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
CN105732464A (zh) 2014-12-31 2016-07-06 杏国新药股份有限公司 一种规模化生产吲哚化合物的方法
CN106008479B (zh) 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
CN105936635B (zh) 2015-03-06 2019-06-21 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的化合物及其应用
WO2016153432A1 (en) 2015-03-23 2016-09-29 Nanyang Polytechnic Drugs from substituted phenyl cinnamyl ketones
CN105481765A (zh) 2015-04-15 2016-04-13 江苏艾凡生物医药有限公司 一类用于治疗心力衰竭的酰腙类衍生物
EP3302488B1 (en) 2015-06-03 2020-09-30 Tairx, Inc. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry
PE20180572A1 (es) 2015-06-18 2018-04-04 Cephalon Inc Derivados de piperidina 1,4-sustituidos
WO2017012579A1 (zh) 2015-07-23 2017-01-26 广东东阳光药业有限公司 取代的吲哚化合物及其使用方法和用途
CN106467541B (zh) 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
KR20170029065A (ko) 2015-09-04 2017-03-15 삼성디스플레이 주식회사 유기 발광 소자
EP3371151A4 (en) 2015-10-09 2019-03-27 Agency For Science, Technology And Research COMPOUNDS FOR THE TREATMENT OF CANCER AND EPIGENETICS
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
CN106946775B (zh) 2016-01-07 2020-04-10 清华大学 一种化合物及其在制备抗丙肝病毒药物中的应用
US11075343B2 (en) 2016-01-18 2021-07-27 Sfc Co., Ltd. Organic light emitting compounds and organic light emitting devices including the same
CN107021964A (zh) 2016-02-01 2017-08-08 广东东阳光药业有限公司 萘啶衍生物及其用途
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
KR20170097820A (ko) 2016-02-18 2017-08-29 삼성디스플레이 주식회사 유기 발광 소자
WO2017141116A1 (en) 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
CN105669546A (zh) 2016-03-09 2016-06-15 遵义医学院 一种二氟烷基取代的吡啶酮或吡喃酮的合成方法
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
CN109069473B (zh) 2016-04-21 2022-09-16 港大科桥有限公司 用于亮肤和减少色素沉着过度的组合物和方法
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
EP3481816B1 (en) 2016-07-07 2020-06-24 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
CN107661333B (zh) 2016-07-27 2020-12-29 清华大学 化合物在治疗肺癌中的应用
CN107759620B (zh) 2016-08-16 2021-11-12 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
EP3503884B1 (en) 2016-08-23 2021-07-21 Neurim Pharmaceuticals Ltd. Pharmaceutical composition for use in treating pruritus and/or itch
CN107773562B (zh) 2016-08-25 2020-04-07 清华大学 化合物在抗登革和寨卡病毒感染中的应用
WO2018054711A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018064498A1 (en) 2016-09-30 2018-04-05 Pairnomix, Llc Methods of treating epilepsy and related neurological conditions
WO2018066812A1 (en) 2016-10-05 2018-04-12 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
CN113480530A (zh) 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
ES2890667T3 (es) 2017-01-25 2022-01-21 Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd Compuesto de profármaco de lanosterol y su uso del mismo
CN108623560A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种喹啉酮酸类衍生物及其制备方法和用途
CN108623562A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种喹啉酮生物碱类化合物及其制备方法和应用
WO2018182221A1 (en) 2017-03-31 2018-10-04 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent device
AU2018243749A1 (en) 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
JP2020100564A (ja) 2017-04-03 2020-07-02 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
EP3664822A4 (en) 2017-08-04 2021-07-07 Axial Therapeutics, Inc. MICROBIAL INDUCED AMYLOID FORMATION INHIBITORS
WO2019046668A1 (en) 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
KR102462422B1 (ko) 2017-10-12 2022-11-03 삼성디스플레이 주식회사 아민계 화합물 및 이를 포함한 유기 발광 소자
AU2018348796B2 (en) 2017-10-13 2024-09-26 Adelaide university Zinc ionophores and uses thereof
AU2018353150B2 (en) 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
US20210213014A1 (en) 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
WO2019089940A1 (en) 2017-11-01 2019-05-09 Pairnomix, Llc Methods of treating epilepsy and related neurological conditions
TWI787416B (zh) 2017-12-12 2022-12-21 日商日本化藥股份有限公司 喹啉-4(1h)-酮衍生物之製造方法
EP3502095A1 (en) 2017-12-22 2019-06-26 Universität Konstanz Compound for use against pathogenic neisseria and haemophilus species and moraxella catarrhalis
CN109608504B (zh) 2017-12-28 2022-04-05 广州华睿光电材料有限公司 有机金属配合物、聚合物、混合物、组合物和有机电子器件
AU2019210332A1 (en) 2018-01-22 2020-09-10 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
CN108558753A (zh) 2018-05-22 2018-09-21 陕西师范大学 采用五羰基铁作为co释放源制备喹诺酮类化合物的方法
CN108610286B (zh) 2018-05-25 2021-12-03 绍兴文理学院 一种2-芳基-4-喹诺酮衍生物及其制备方法和应用
WO2019228404A1 (zh) 2018-05-31 2019-12-05 信达生物制药(苏州)有限公司 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
EP3807264A1 (en) 2018-06-12 2021-04-21 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
CN112469718B (zh) 2018-07-19 2022-08-30 深圳市瓴方生物医药科技有限公司 氮杂吲哚衍生物及其作为FGFR和C-Met抑制剂的应用
US20220340875A1 (en) 2018-07-19 2022-10-27 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds
WO2020033960A1 (en) 2018-08-10 2020-02-13 Emory University Substituted Dihydroxyflavone Derivatives, Compositions, and Methods Related Thereto
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
US20210300898A1 (en) 2018-09-21 2021-09-30 Jnana Therapeutics, Inc. Small molecules targeting mutant mammalian proteins
CN113194942A (zh) 2018-10-15 2021-07-30 Ck生物技术股份有限公司 用于抑制和/或治疗生长相关疾病和/或其临床病症的组合物和方法
WO2020079569A1 (en) 2018-10-15 2020-04-23 Ck Biotechnology Co. Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof
WO2020094156A1 (zh) 2018-11-11 2020-05-14 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
CN111484477B (zh) 2019-01-29 2022-07-08 博瑞生物医药(苏州)股份有限公司 一种苯并吡啶酮杂环化合物及其用途
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
WO2020177729A1 (zh) 2019-03-06 2020-09-10 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
US11638705B2 (en) 2019-04-19 2023-05-02 Academia Sinica 4(1H)-quinolone derivatives and uses thereof
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
CN110498784B (zh) 2019-05-20 2022-06-14 广东克冠达医药科技有限公司 一类川陈皮素衍生物或其药学上可接受的盐及其制备方法和应用
WO2020255156A1 (en) 2019-06-19 2020-12-24 Dr Reddy's Institute Of Life Sciences Heterocyclic compounds as lipoxygenase inhibitors
CN110429187B (zh) 2019-07-05 2020-12-08 武汉华星光电半导体显示技术有限公司 薄膜电致发光器件及其制备方法、电子设备
CN110372588B (zh) 2019-08-29 2022-12-06 成都理工大学 一种4-胺基喹啉化合物及其制备方法和应用
CN110790752B (zh) 2019-11-12 2022-08-23 陕西师范大学 一种(异)喹啉和喹喔啉取代的黄酮及喹诺酮衍生物的合成方法
KR102711647B1 (ko) 2020-07-07 2024-09-30 (주)아이랩 신규한 tnf 활성 억제제 화합물 및 이의 약학적으로 허용가능한 염
JP7853310B2 (ja) * 2021-03-02 2026-04-28 フレア・セラピューティクス・インコーポレーテッド Pparg逆アゴニストおよびその使用
JP2024529534A (ja) * 2021-08-05 2024-08-06 フレア・セラビューティクス・インコーポレーテッド Pparg逆アゴニストおよびその使用
SMT202500447T1 (it) * 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028427A1 (en) * 2006-09-04 2008-03-13 Univerzita Palackeho Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization
CN105982884B (zh) * 2015-02-25 2019-05-24 上海中医药大学 一种补骨脂二氢黄酮甲醚及其类似物的用途
CN107522657B (zh) * 2017-09-28 2020-06-26 上海中医药大学 一种具有ppar多重激动活性的化合物及其制备方法和应用
WO2019246343A1 (en) * 2018-06-21 2019-12-26 Taiwanj Pharmaceuticals Co., Ltd. Nadph oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Uniprot", Database accession no. P37231-2
HINO KATSUHIKO ET AL: "Nonsteroidal antiinflammatory agents. III. Synthesis of the metabolites of 10,11-dihydro-8,.ALPHA.-dimethyl-11-oxodibenz(b,f)oxepin-2-acetic acid (bermoprofen).", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 36, no. 9, 1 January 1988 (1988-01-01), JP, pages 3462 - 3467, XP093006020, ISSN: 0009-2363, DOI: 10.1248/cpb.36.3462 *
LI YANG ET AL: "An unexpected synthesis and application of ethyl 2,4-bis(chloromethyl)-6-iodoquinoline-3-carboxylate", RESEARCH ON CHEMICAL INTERMEDIATES, AMSTERDAM, NL, vol. 46, no. 4, 29 January 2020 (2020-01-29), pages 2215 - 2228, XP037062814, ISSN: 0922-6168, [retrieved on 20200129], DOI: 10.1007/S11164-020-04088-W *
ROY R. U. ET AL: "Anticancer evaluation of azetidinone and thiazolidinone derivatives of quinolone", INTERNATIONAL JOURNAL OF CHEMICAL SCIENCES, vol. 3, no. 3, 1 January 2005 (2005-01-01), IN, pages 529 - 536, XP055923708, ISSN: 0972-768X, Retrieved from the Internet <URL:chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.tsijournals.com/articles/anticancer-evaluation-of-azetidinone-and-thiazolidinone-derivatives-of-quinolone.pdf> *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4489863A1 (en) * 2022-03-08 2025-01-15 Flare Therapeutics, Inc. Pparg inverse agonists and uses thereof
WO2024221455A1 (en) * 2023-04-28 2024-10-31 Flare Therapeutics, Inc. Crystalline forms of 3- (5, 7-difluoro-4-oxo-1, 4-dihydroquinolin-2-yl) -4- (methylsulfonyl) benzonitrile
WO2024227070A1 (en) * 2023-04-28 2024-10-31 Flare Therapeutics Inc. Crystalline forms of 3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile
WO2025090706A1 (en) 2023-10-27 2025-05-01 Flare Therapeutics Inc. Pparg inverse agonists and immunotherapies for treating cancer
WO2025098515A1 (en) * 2023-11-10 2025-05-15 Danatlas Pharmaceuticals Co., Ltd. Heterocyclic derivatives, compositions and uses thereof
WO2026046259A1 (zh) * 2024-08-27 2026-03-05 杭州英创医药科技有限公司 作为pparg反向激动剂的化合物

Also Published As

Publication number Publication date
LT4426434T (lt) 2025-12-29
MA67105B1 (fr) 2025-11-28
US11820747B2 (en) 2023-11-21
EP4653053A1 (en) 2025-11-26
EP4426434B1 (en) 2025-08-20
PL4426434T3 (pl) 2026-04-27
RS67425B1 (sr) 2025-12-31
PE20250739A1 (es) 2025-03-10
US20230331678A1 (en) 2023-10-19
MX2024005405A (es) 2024-11-08
CN119677720A (zh) 2025-03-21
US20250084038A1 (en) 2025-03-13
SI4426434T1 (sl) 2026-02-27
IL312547A (en) 2024-07-01
DK4426434T3 (da) 2025-11-10
MD4426434T2 (ro) 2026-03-31
TW202334089A (zh) 2023-09-01
ES3053082T3 (en) 2026-01-19
HRP20251438T1 (hr) 2026-01-02
SMT202500447T1 (it) 2026-01-12
EP4426434A1 (en) 2024-09-11
PT4426434T (pt) 2025-11-24
AU2022380979A1 (en) 2024-06-06
KR20240144096A (ko) 2024-10-02
CL2024001346A1 (es) 2024-10-11
CA3237199A1 (en) 2023-05-11
FI4426434T3 (fi) 2025-11-24
JP2025508272A (ja) 2025-03-24

Similar Documents

Publication Publication Date Title
EP4426434B1 (en) Pparg inverse agonists and uses thereof
JP7039802B2 (ja) Rho-関連プロテインキナーゼ阻害剤、rho-関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
EP4380928A1 (en) Pparg inverse agonists and uses thereof
CN115716840A (zh) 一种具有kras突变蛋白抑制作用的杂环化合物及其药物组合和用途
JP7853310B2 (ja) Pparg逆アゴニストおよびその使用
JP2018534326A (ja) Ror−ガンマのモジュレーター
BG63778B1 (bg) Ароматни съединения и фармацевтични състави, които ги съдържат
AU2016279965A1 (en) Spiro[cyclobutane-1,3&#39;-indolin]-2&#39;-one derivatives as bromodomain inhibitors
US20250186425A1 (en) Pparg inverse agonists and uses thereof
US20250289812A1 (en) Compound for treating thrombotic diseases
WO2023172846A1 (en) Pparg inverse agonists and uses thereof
HK40118248A (en) Pparg inverse agonists and uses thereof
HK40118248B (en) Pparg inverse agonists and uses thereof
EA051641B1 (ru) Обратные агонисты pparg и их применения
CN116096708A (zh) 用作用于疗法的蛋白激酶抑制剂的2-氧代-n-(4-(嘧啶-4-基氧基/硫基)苯基)-1,2-二氢吡啶-3-甲酰胺的衍生物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22809321

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3237199

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2024526592

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 000994-2024

Country of ref document: PE

Ref document number: 12024551055

Country of ref document: PH

Ref document number: 2401002832

Country of ref document: TH

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024008742

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2022380979

Country of ref document: AU

Ref document number: AU2022380979

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 202417040219

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2022809321

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022380979

Country of ref document: AU

Date of ref document: 20221101

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2022809321

Country of ref document: EP

Effective date: 20240603

WWE Wipo information: entry into national phase

Ref document number: 202280086503.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11202403083Q

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 112024008742

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240502

WWP Wipo information: published in national office

Ref document number: 202280086503.8

Country of ref document: CN

WWG Wipo information: grant in national office

Ref document number: 2022809321

Country of ref document: EP